180 related articles for article (PubMed ID: 37824212)
21. Activated FGFR3 prevents subchondral bone sclerosis during the development of osteoarthritis in transgenic mice with achondroplasia.
Okura T; Matsushita M; Mishima K; Esaki R; Seki T; Ishiguro N; Kitoh H
J Orthop Res; 2018 Jan; 36(1):300-308. PubMed ID: 28520086
[TBL] [Abstract][Full Text] [Related]
22. Molecular basis for the treatment of achondroplasia.
Yamanaka Y; Ueda K; Seino Y; Tanaka H
Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
[TBL] [Abstract][Full Text] [Related]
23. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
24. Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible.
Biosse Duplan M; Komla-Ebri D; Heuzé Y; Estibals V; Gaudas E; Kaci N; Benoist-Lasselin C; Zerah M; Kramer I; Kneissel M; Porta DG; Di Rocco F; Legeai-Mallet L
Hum Mol Genet; 2016 Jul; 25(14):2997-3010. PubMed ID: 27260401
[TBL] [Abstract][Full Text] [Related]
25. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
[TBL] [Abstract][Full Text] [Related]
26. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3.
Naski MC; Colvin JS; Coffin JD; Ornitz DM
Development; 1998 Dec; 125(24):4977-88. PubMed ID: 9811582
[TBL] [Abstract][Full Text] [Related]
27. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
[TBL] [Abstract][Full Text] [Related]
28. Expanding horizons of achondroplasia treatment: current options and future developments.
Fafilek B; Bosakova M; Krejci P
Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
[TBL] [Abstract][Full Text] [Related]
29. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
[TBL] [Abstract][Full Text] [Related]
30. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.
Saint-Laurent C; Garcia S; Sarrazy V; Dumas K; Authier F; Sore S; Tran A; Gual P; Gennero I; Salles JP; Gouze E
PLoS One; 2018; 13(4):e0195876. PubMed ID: 29652901
[TBL] [Abstract][Full Text] [Related]
31. PTH has the potential to rescue disturbed bone growth in achondroplasia.
Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
[TBL] [Abstract][Full Text] [Related]
32. Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants.
Chang IJ; Sun A; Bouchard ML; Kamps SE; Hale S; Done S; Goldberg MJ; Glass IA
Am J Med Genet A; 2018 Jul; 176(7):1675-1679. PubMed ID: 30160829
[TBL] [Abstract][Full Text] [Related]
33. Activated FGFR3 promotes bone formation via accelerating endochondral ossification in mouse model of distraction osteogenesis.
Osawa Y; Matsushita M; Hasegawa S; Esaki R; Fujio M; Ohkawara B; Ishiguro N; Ohno K; Kitoh H
Bone; 2017 Dec; 105():42-49. PubMed ID: 28802681
[TBL] [Abstract][Full Text] [Related]
34. PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation.
Yamanaka Y; Tanaka H; Koike M; Nishimura R; Seino Y
J Bone Miner Res; 2003 Aug; 18(8):1395-403. PubMed ID: 12929929
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
[TBL] [Abstract][Full Text] [Related]
36. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
37. FGFR3 targeting strategies for achondroplasia.
Laederich MB; Horton WA
Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
[TBL] [Abstract][Full Text] [Related]
38. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
Yamashita A; Morioka M; Kishi H; Kimura T; Yahara Y; Okada M; Fujita K; Sawai H; Ikegawa S; Tsumaki N
Nature; 2014 Sep; 513(7519):507-11. PubMed ID: 25231866
[TBL] [Abstract][Full Text] [Related]
39. Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias.
Zheng C; Lin X; Xu X; Wang C; Zhou J; Gao B; Fan J; Lu W; Hu Y; Jie Q; Luo Z; Yang L
EBioMedicine; 2019 Feb; 40():695-709. PubMed ID: 30685387
[TBL] [Abstract][Full Text] [Related]
40. Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells.
Thompson LM; Raffioni S; Wasmuth JJ; Bradshaw RA
Mol Cell Biol; 1997 Jul; 17(7):4169-77. PubMed ID: 9199352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]